Department of General, Visceral and Transplant Surgery, University Hospital of Munich, Munich 81377, Germany.
Klinikum Freising, Freising, Germany.
Int J Colorectal Dis. 2023 Jul 7;38(1):187. doi: 10.1007/s00384-023-04453-2.
Enterovaginal fistulas represent a serious complication of various diseases and therapeutic procedures, often associated with complicated clinical courses and massive impairment of quality of life. As underlying conditions and procedures are multifarious, therapeutic approaches are challenging and have to be tailored individually. As the therapeutic management is complex and individualized, multiple surgical interventions might be necessary.
The aim of this study was to identify possible predictors for outcome in the treatment enterovaginal fistula patients. The study was realized as a retrospective analysis. Ninety-two patients treated with enterovaginal fistulas between 2004 and 2016 were analyzed. Patient characteristics, therapeutic data, and endoscopic findings were stratified according to etiology, closure rate and time, as well as recurrence of fistula. Main outcome measure was the overall rate of fistula closure.
Overall therapeutic success rate was 67.4%. Postoperatively derived fistulas were most frequent (40.2%), mainly after rectal surgery (59.5%). Postoperative and non-IBD-inflammation associated fistulas had better outcome than IBD-, radiotherapy-, and tumor-related fistulas (p = 0.001). Successful fistula closure was observed more frequently after radical surgical interventions, best results observed after transabdominal surgery (p < 0.001). Fistula recurrence was also less frequently observed after radical surgical therapies (p = 0.029). A temporary stoma was associated with higher incidence of fistula closure (p = 0.013) and lower incidence of fistula recurrence (p = 0.042) in the postoperative subgroup, as well as shortened therapy period in all groups (p = 0.031).
Enterovaginal fistulas are a result of various etiologies, and treatment should be adjusted accordingly. A very sustainable, rapid, and persistent therapeutic success can be expected after radical surgical approaches with temporary diverting stoma. This is especially true for postoperatively derived fistulas.
肠阴道瘘是各种疾病和治疗过程的严重并发症,常伴有复杂的临床病程和生活质量的严重损害。由于基础疾病和治疗过程多种多样,治疗方法具有挑战性,需要个体化定制。由于治疗管理复杂且个体化,可能需要多次手术干预。
本研究旨在确定治疗肠阴道瘘患者结局的可能预测因素。该研究为回顾性分析。分析了 2004 年至 2016 年间接受肠阴道瘘治疗的 92 例患者。根据病因、闭合率和时间以及瘘管复发情况,对患者特征、治疗数据和内镜检查结果进行分层。主要观察指标为瘘管总体闭合率。
总治疗成功率为 67.4%。术后衍生的瘘管最常见(40.2%),主要发生在直肠手术后(59.5%)。与 IBD、放疗和肿瘤相关的瘘管相比,术后和非 IBD 炎症相关的瘘管结局更好(p=0.001)。根治性手术干预后,瘘管闭合更为常见,经腹手术效果最佳(p<0.001)。根治性手术治疗后,瘘管复发也较少(p=0.029)。在术后组中,临时造口与瘘管闭合率较高(p=0.013)和瘘管复发率较低(p=0.042)相关,并且所有组的治疗时间均缩短(p=0.031)。
肠阴道瘘是多种病因引起的,治疗应相应调整。对于有临时转流造口的根治性手术方法,可预期获得非常持久、快速和持续的治疗成功。对于术后衍生的瘘管尤其如此。